OncoMatch/Clinical Trials/NCT06908694
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Is NCT06908694 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Semaglutide Pen Injector for prostate cancer.
Treatment: Semaglutide Pen Injector — GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Must have received: androgen deprivation therapy (gonadotropin releasing hormone agonist, gonadotropin releasing hormone antagonist, androgen receptor pathway inhibitor) — receiving or planned to receive
Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
Cannot have received: GLP-1 receptor agonist
Taking a GLP-1 RA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06908694 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior GLP-1 receptor agonist disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages